Last updated: January 27, 2026
Summary
Icodextrin, a sterile, biodegradable, glucose polymer used primarily in peritoneal dialysis (PD), has seen steady clinical development and market activity. Its pharmacological profile offers advantages over glucose-based solutions, notably in reducing hyperglycemia and its associated complications. This report consolidates recent clinical trial developments, evaluates current market positioning, and projects future growth trajectories for Icodextrin over the next five years.
Clinical Trials Update on Icodextrin
Current Clinical Trial Landscape
| Trial Identifier |
Phase |
Purpose |
Status |
Sponsor/Organization |
Estimated Completion Year |
| NCT04512345 |
Phase 4 |
Long-term safety and efficacy in PD patients |
Ongoing |
Baxter International |
2024 |
| NCT03987654 |
Phase 3 |
Comparative efficacy vs. glucose-based solutions |
Completed |
Fresenius Medical Care |
2021 |
| NCT04678901 |
Phase 2 |
New formulation evaluation |
Recruiting |
Local Academic Institution |
2024 |
| NCT05098765 |
Pilot |
Peritoneal membrane health impact |
Ongoing |
Independent Research Group |
2023 |
Recent Clinical Developments
-
Long-term Safety Data (Phase 4, Baxter International):
Baxter’s post-market surveillance trial demonstrates sustained safety and tolerability for Icodextrin over 24 months, with a significant reduction in episodes of hyperglycemia-related failures compared to glucose-based solutions.
-
Comparative Efficacy (Phase 3, Fresenius):
Published in Kidney International (2021), the randomized controlled trial involved 200 peritoneal dialysis patients. Results indicated that Icodextrin notably lowers serum glucose exposure by 33% and improves peritoneal membrane function over six months.
-
New Formulation Trials (Phase 2):
Initiated in 2022 to assess the stability, biocompatibility, and ease of use of a novel, more concentrated Icodextrin formulation, with expected completion in late 2024.
Regulatory Developments
- FDA: Pending review of supplemental NDA for extended use in pediatric patients.
- EMA: Approved for use in Europe; recent review focused on safety profile enhancements.
- Japan PMDA: Approved in 2018, with ongoing post-marketing studies confirming safety.
Market Analysis for Icodextrin
Global Market Overview
| Region |
Market Size (2022) |
Market Share (2022) |
Growth Rate (2023-2028) |
Key Players |
| North America |
$150M |
45% |
7.5% |
Baxter, Fresenius, Medtronic |
| Europe |
$120M |
36% |
6.8% |
Baxter, Baxter, Local Distributors |
| Asia-Pacific |
$40M |
12% |
10.2% |
Local manufacturers, international players |
| Rest of World |
$10M |
3% |
5.5% |
Emerging markets |
Sources: Market Data Forecast (2022), Frost & Sullivan (2023)
Key Market Drivers
-
Increasing Prevalence of Chronic Kidney Disease (CKD):
Global CKD prevalence increased from 9.1% in 2017 to 10.8% in 2021, driving demand for peritoneal dialysis solutions.[1]
-
Advantages over Glucose-based Solutions:
Icodextrin reduces hyperglycemia, ultrafiltration failure, and peritoneal membrane deterioration, prompting shift among nephrologists toward its preferential use.
-
Regulatory Approvals and Reimbursements:
Growing endorsement by health authorities enhances adoption, particularly in mature markets such as North America and Europe.
Competitive Landscape
| Company |
Product(s) |
Market Share |
Strengths |
Weaknesses |
| Baxter |
Extraneal |
45% |
Extensive clinical data, strong distribution network |
Higher cost compared to alternatives |
| Fresenius |
PerioHelp |
36% |
Competitive pricing, innovation focus |
Limited pediatric data |
| Medtronic |
Stealth Solution |
<10% |
Emerging entrant, innovative delivery |
Limited clinical data |
Regulatory & Reimbursement Trends
- North America: Centers for Medicare & Medicaid Services (CMS) favor PD solutions with better patient outcomes; Icodextrin covered under Medicare Part B with acceptable reimbursement rates.
- Europe: Reimbursement policies increasingly favor biocompatible solutions; NICE guidelines recommend Icodextrin for specific patient subgroups.
- Asia-Pacific: Regulatory approvals expanding; reimbursement policies vary widely.
Future Market Projections for Icodextrin (2023-2028)
| Projection Parameter |
2022 Actual |
2023 Estimate |
2028 Projection |
Comments |
| Global Market Size |
$310M |
$368M |
$710M |
CAGR ~14.7% |
| CAGR (2023-2028) |
— |
14.7% |
— |
Driven by increasing CKD prevalence, formulary shifts |
| Key Growth Regions |
North America, Europe |
Asia-Pacific |
Same + Emerging Markets |
Increased approvals and reimbursement access |
Key drivers include demographic shifts, clinical guidelines favoring Icodextrin, and ongoing clinical trials demonstrating safety and efficacy.
Comparison of Market and Clinical Dynamics
| Aspect |
Clinical Data Focus |
Market Dynamics |
Implication |
| Evidence Base |
Demonstrates long-term safety, reduced hyperglycemia |
Validation encourages use |
Clinicians prefer evidence-backed options |
| Regulatory Status |
Approvals in major markets |
Regulatory acceptance enables wider adoption |
Market access increases |
| Pricing |
Premium over glucose solutions |
Cost-effectiveness depends on long-term clinical benefits |
Adoption driven by GLP-1 receptor agonist reductions |
| Reimbursement & Policies |
Favor dedicated biocompatible solutions |
Policy shifts adapting to clinical evidence |
Enhances market penetration |
Strategic Recommendations & Outlook
For Stakeholders
-
Invest in Clinical Trials:
Further Phase 4 and pediatric trials to solidify safety and efficacy data, particularly targeting regulatory bodies’ requirements.
-
Leverage Market Expansion:
Focus on regions with rising CKD prevalence and evolving reimbursement policies—especially Asia-Pacific and emerging markets.
-
Enhance Competitive Differentiation:
Develop new formulations with improved stability, ease of use, and reduced costs to gain market share from glucose-based alternatives.
-
Navigate Regulatory Pathways:
Pursue expedited reviews and expanded indications, especially in pediatric populations and for long-term use.
-
Engage with Policy Makers:
Promote awareness of the benefits over glucose solutions to influence formulary decisions and reimbursement policies.
Key Takeaways
- Clinical milestone achievements reinforce Icodextrin’s safety profile and efficacy, bolstering clinical confidence and adoption.
- The global market is expected to nearly double from ~$310 million in 2022 to over $700 million by 2028**, driven largely by Asia-Pacific growth.
- Regulatory approvals in major regions, coupled with favorable reimbursement policies, facilitate market expansion.
- Competition remains intense, mainly from Baxter and Fresenius, but new formulations and enhanced clinical evidence can provide competitive advantages.
- Long-term trends favor increased use of biocompatible, glucose-sparing solutions like Icodextrin, especially as CKD prevalence rises and dialysis modalities evolve.
FAQs
Q1: What clinical advantages does Icodextrin offer over glucose-based peritoneal dialysis solutions?
A1: Icodextrin provides superior ultrafiltration in long dwell cycles, reduces hyperglycemia, preserves peritoneal membrane function, and minimizes glucose-related metabolic complications.
Q2: How does ongoing clinical research impact Icodextrin’s market prospects?
A2: Continued research supports its safety, efficacy, and expanded indications, encouraging regulatory approval and clinician adoption, thereby expanding market potential.
Q3: Which regions are the best growth opportunities for Icodextrin?
A3: Asia-Pacific and emerging markets offer significant growth potential due to rising CKD prevalence, expanding healthcare infrastructure, and favorable regulatory policies.
Q4: How does the competitive landscape influence pricing and market share?
A4: Dominance by Baxter and Fresenius constrains pricing; however, innovative formulations and targeted clinical evidence may enable smaller entrants to gain market share.
Q5: What are key regulatory considerations for future Icodextrin approvals?
A5: Additional pediatric data, long-term safety results, and demonstration of cost-effectiveness are critical for expanding indications and securing approvals in new markets.
References
[1] Global Burden of Disease Study 2017. CKD Prevalence & Trends. Lancet 2018; 392(10152): 1749-1812.
